Do analysts recommend ADXS or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXS or PBM more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Psyence Biomedical N/A N/A N/A

Do analysts prefer PBM or PYRGF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PBM or PYRGF more profitable?

Psyence Biomedical has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A PyroGenesis Canada -115.14% N/A -60.81%

Does the media prefer PBM or PYRGF?

In the previous week, Psyence Biomedical and Psyence Biomedical both had 3 articles in the media. Psyence Biomedical's average media sentiment score of 0.72 beat PyroGenesis Canada's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PBM or UG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend MIRA or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, MIRA or PBM?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A Psyence Biomedical N/A N/A -$6.94M $25.34 0.17

Is MIRA or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Psyence Biomedical N/A N/A N/A

Do analysts recommend PBM or NNVC?

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 365.12%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts plainly believe NanoViricides is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, PBM or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.17 NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PBM or NNVC more profitable?

Psyence Biomedical's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Does the media prefer PBM or NNVC?

In the previous week, Psyence Biomedical and Psyence Biomedical both had 3 articles in the media. Psyence Biomedical's average media sentiment score of 0.72 beat NanoViricides' score of -0.19 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Psyence Biomedical (PBM) Competitors

$4.27 +0.05 (+1.18%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$4.35 +0.08 (+1.87%)

As of 08/25/2026 05:36 PM Eastern

Compare

PBM vs. ADXS, PYRGF, UG, MIRA, and NNVC

Should you buy Psyence Biomedical stock or one of its competitors? Psyence Biomedical's main competitors and comparable companies include Ayala Pharmaceuticals (ADXS), PyroGenesis Canada (PYRGF), United-Guardian (UG), MIRA Pharmaceuticals (MIRA), and NanoViricides (NNVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Psyence Biomedical compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Psyence Biomedical	N/A	N/A	N/A

In the previous week, Psyence Biomedical had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Psyence Biomedical and 0 mentions for Ayala Pharmaceuticals. Psyence Biomedical's average media sentiment score of 0.72 beat Ayala Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Psyence Biomedical	Positive

Psyence Biomedical has lower revenue, but higher earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17

Summary

Psyence Biomedical beats Ayala Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to PyroGenesis Canada?

Psyence Biomedical (NASDAQ:PBM) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Psyence Biomedical has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17
PyroGenesis Canada	$9.14M	3.69	-$21.12M	-$0.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Psyence Biomedical and Psyence Biomedical both had 3 articles in the media. Psyence Biomedical's average media sentiment score of 0.72 beat PyroGenesis Canada's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Psyence Biomedical has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
PyroGenesis Canada	-115.14%	N/A	-60.81%

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Psyence Biomedical has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Psyence Biomedical beats PyroGenesis Canada on 9 of the 11 factors compared between the two stocks.

How does Psyence Biomedical compare to United-Guardian?

Psyence Biomedical (NASDAQ:PBM) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Psyence Biomedical has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

United-Guardian has higher revenue and earnings than Psyence Biomedical. Psyence Biomedical is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17
United-Guardian	$10.55M	3.16	$2.11M	$0.54	13.46

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Psyence Biomedical had 1 more articles in the media than United-Guardian. MarketBeat recorded 3 mentions for Psyence Biomedical and 2 mentions for United-Guardian. Psyence Biomedical's average media sentiment score of 0.72 beat United-Guardian's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Positive
United-Guardian	Neutral

United-Guardian has a net margin of 22.01% compared to Psyence Biomedical's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Psyence Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
United-Guardian	22.01%	22.24%	19.12%

Summary

United-Guardian beats Psyence Biomedical on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MIRA Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Psyence Biomedical had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 3 mentions for Psyence Biomedical and 1 mentions for MIRA Pharmaceuticals. Psyence Biomedical's average media sentiment score of 0.72 beat MIRA Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Psyence Biomedical	Positive

Psyence Biomedical's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Psyence Biomedical	N/A	N/A	N/A

Summary

Psyence Biomedical beats MIRA Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Psyence Biomedical compare to NanoViricides?

Psyence Biomedical (NASDAQ:PBM) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Psyence Biomedical's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Psyence Biomedical has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 365.12%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts plainly believe NanoViricides is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, Psyence Biomedical and Psyence Biomedical both had 3 articles in the media. Psyence Biomedical's average media sentiment score of 0.72 beat NanoViricides' score of -0.19 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Psyence Biomedical beats NanoViricides on 8 of the 12 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.68M	$12.54B	$7.35B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	0.17	778.14	270.96	24.14
Price / Sales	N/A	754.40	634.76	101.59
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.58	12.02	13.14	6.25
Net Income	-$6.94M	$2.80B	$3.46B	$347.86M
7 Day Performance	4.15%	2.88%	1.52%	0.98%
1 Month Performance	44.75%	6.55%	8.82%	5.24%
1 Year Performance	-78.58%	8.09%	26.08%	17.04%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.6758 of 5 stars	$4.27 +1.2%	N/A	-78.8%	$9.68M	N/A	0.17	N/A	Short Interest Decrease
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
PYRGF PyroGenesis Canada	N/A	$0.15 -0.9%	N/A	-30.8%	$33.39M	$9.14M	N/A	90
UG United-Guardian	1.2588 of 5 stars	$7.13 +1.1%	N/A	-11.9%	$32.39M	$10.55M	13.20	20	Short Interest Increase
MIRA MIRA Pharmaceuticals	0.4804 of 5 stars	$0.71 -7.8%	N/A	-45.4%	$32.36M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. ADXS, PYRGF, UG, MIRA, and NNVC

How does Psyence Biomedical compare to Ayala Pharmaceuticals?

Summary

How does Psyence Biomedical compare to PyroGenesis Canada?

Summary

How does Psyence Biomedical compare to United-Guardian?

Summary

How does Psyence Biomedical compare to MIRA Pharmaceuticals?

Summary

How does Psyence Biomedical compare to NanoViricides?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. ADXS, PYRGF, UG, MIRA, and NNVC

How does Psyence Biomedical compare to Ayala Pharmaceuticals?

Do analysts recommend ADXS or PBM?

Do institutionals and insiders hold more shares of ADXS or PBM?

Which has more risk & volatility, ADXS or PBM?

Is ADXS or PBM more profitable?

Does the media refer more to ADXS or PBM?

Which has preferable earnings & valuation, ADXS or PBM?

Summary

How does Psyence Biomedical compare to PyroGenesis Canada?

Which has higher earnings and valuation, PBM or PYRGF?

Do analysts prefer PBM or PYRGF?

Does the media prefer PBM or PYRGF?

Is PBM or PYRGF more profitable?

Do institutionals & insiders have more ownership in PBM or PYRGF?

Which has more risk & volatility, PBM or PYRGF?

Summary

How does Psyence Biomedical compare to United-Guardian?

Which has more risk and volatility, PBM or UG?

Do analysts rate PBM or UG?

Which has preferable valuation and earnings, PBM or UG?

Do institutionals and insiders have more ownership in PBM or UG?

Does the media prefer PBM or UG?

Is PBM or UG more profitable?

Summary

How does Psyence Biomedical compare to MIRA Pharmaceuticals?

Do analysts recommend MIRA or PBM?

Which has more volatility & risk, MIRA or PBM?

Which has better valuation and earnings, MIRA or PBM?

Do insiders and institutionals hold more shares of MIRA or PBM?

Does the media favor MIRA or PBM?

Is MIRA or PBM more profitable?

Summary

How does Psyence Biomedical compare to NanoViricides?

Is PBM or NNVC more profitable?

Do institutionals & insiders believe in PBM or NNVC?

Which has more risk and volatility, PBM or NNVC?

Do analysts recommend PBM or NNVC?

Which has stronger valuation & earnings, PBM or NNVC?

Does the media prefer PBM or NNVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools